Actinogen Medical Ltd has released a press release.
R&D Tax Incentive Rebate received of A$1.435 million
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Actinogen Medical FY21 Results- Progressing the Pipeline
- Actinogen completes global patent family grant
- First Patient Enrolled in XanaMIA trial
- Actinogen receives positive Pre-IND FDA advice for FXS
- Clinical progress for XanaMIA trial
Later from Actinogen Medical
- ACW announces open IND for Phase 2 Fragile X trial & LOI
- Program Expansion & Capital Raising
- Strategic Update & Capital Raising Investor Presentation
- XanaMIA Part A trial achieves target enrolment
- ACW Strategic Collaboration with Oxford Uni Researchers
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical